(Q41500435)

1 October 2017

1 reference

title

Prostate cancer diagnosis and management (English)

1 reference

1 October 2017

1 reference

1 reference

Mark Frydenberg

1

1 reference

1 October 2017

Phillip David Stricker

series ordinal

2

1 reference

1 October 2017

Keith W Kaye

series ordinal

3

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

1 October 2017

1 reference

1 October 2017

volume

349

1 reference

1 October 2017

issue

9066

1 reference

1 October 2017

page(s)

1681-1687

1 reference

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

The Clinical Usefulness of Prostate Specific Antigen: Update 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Impact of prostate-specific antigen screening on the natural history of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

The diagnosis of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Prostate cancer kills: Strategy to reduce deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Expectant management of early stage prostatic cancer: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Quality-of-life outcomes in men treated for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Studies of genetic factors in prostate cancer in a twin population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Family history and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

An economic rationale for prostate cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Accuracy of Digital Rectal Examination and Transrectal Ultrasonography in Localizing Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Mini-laparotomy staging pelvic lymphadenectomy (minilap). Alternative to standard and laparoscopic pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Influence of Preoperative Positive Seminal Vesicle Biopsy on the Staging of Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Control of prostate cancer with radiotherapy: long-term results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

A critique of the decision analysis for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Early Prostate Cancer: The National Results of Radiation Treatment from the Patterns of Care and Radiation Therapy Oncology Group Studies With Prospects for Improvement with Conformal Radiation and Adjuvant Androgen Deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Treatment of clinical local failure after radiation therapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Deferred treatment of low grade stage T3 prostate cancer without distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Definitive radiation therapy for localized prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Prognostic significance of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Estrogens in the Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Quality of life after palliative radiotherapy in patients with hormone‐resistant prostate cancer: single institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Radiotherapy for regionally localized hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Hormone refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2907393-X

7 January 2021

10.1016/S0140-6736(96)07393-X

Identifiers

DOI

1 reference

1 October 2017

1 reference